Phase 3 Study of Taletrectinib vs Placebo as an Adjuvant Therapy in ROS1 Positive NSCLC (TRUST-IV)
A Phase 3 Multicenter Double-blind Randomized Study of Taletrectinib Versus Placebo in Patients With ROS1-Fusion Positive Stage IB-IIIA Non-Small Cell Lung Cancer Who Have Undergone Complete Tumor Resection
Sponsor: Nuvation Bio Inc.
This observational or N/A phase trial investigates Non-small Cell Lung Cancer (NSCLC) and is currently actively recruiting participants. Nuvation Bio Inc. leads this study, which shows 5 recorded versions since 2025 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
5 versions recorded-
Apr 16, 2026 — Present [daily]
Recruiting
Phase: PHASE3 → None
-
Feb 2026 — Apr 2026 [monthly]
Recruiting PHASE3
-
Jan 2026 — Feb 2026 [monthly]
Recruiting PHASE3
-
Nov 2025 — Jan 2026 [monthly]
Recruiting PHASE3
-
Oct 2025 — Nov 2025 [monthly]
Recruiting PHASE3
First recorded
Aug 2025
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
The purpose of this phase 3 multicenter double-blind randomized study is to assess the use of taletrectinib in the early-stage non-small cell lung cancer (NSCLC). The study compares taletrectinib (study drug) versus placebo (sugar pill) in patients with ROS1-fusion positive stage IB, II, IIIA NSCLC. The study will evaluate if taletrectinib is better than placebo at preventing the participant's disease from coming back after the participant's lung tumor was removed.
Contact Information
- Nuvation Bio Inc.
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Austin, United States , Beijing, China , Beijing, China , Boise, United States , Boston, United States , Chengdu, China , Fairfax, United States , Guangzhou, China , Hangzhou, China , Houston, United States and 19 more locations